ROPIVACAINE B.BRAUN (ropivacaïne)

Key points

Favourable opinion for reimbursement in acute pain management in paediatric patients via single and continuous nerve block in infants (from 1 year) and children (≤12 years).

What therapeutic improvement?

No clinical added value in the therapeutic strategy.

Role in the care pathway?

The local anaesthetics generally used for paediatric locoregional anaesthesia are amine amide-type local anaesthetics. The long-acting local anaesthetics ropivacaine and levobupivacaine are less cardiotoxic than bupivacaine.

These local anaesthetics (ropivacaine, bupivacaine and levobupivacaine) have been available to clinicians for several decades, with well-established medical use. While their pharmacological effect is a little different, the possibility of varying the concentration depending on the effect sought (anaesthesia or analgesia) makes locoregional anaesthetic solutions comparable for postoperative analgesic use.

Role of ROPIVACAINE B. BRAUN 2 mg/ml (ropivacaine) in the care pathway:

The medical use of ropivacaine has been well established for several years, with a reported efficacy in terms of control of analgesia and improvement in postoperative care. The risk of toxicity, which exists for all local anaesthetics, makes close monitoring necessary, along with use in a paediatric anaesthesia setting.

Consequently, ROPIVACAINE B. BRAUN 2 mg/ml (ropivacaine) is a first-line treatment in acute pain management in paediatric patients: single and continuous nerve block in infants (from 1 year) and children (≤12 years).

The clinical data available does not enable a conclusion to be reached with respect to the contribution of ropivacaine compared to the other local anaesthetics available in terms of efficacy and safety.